1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

PHARMACOKINETIC ATTRIBUTES OF INTRANASAL DELIVERY: CASE STUDIES AND NEW OPPORTUNITIES

PHARMACOKINETIC ATTRIBUTES OF INTRANASAL DELIVERY: CASE STUDIES AND NEW OPPORTUNITIES

  1. Anonymous
    Costantino, H.R., Sileno, A.P., Johnson, P.H., 2005
    ONDrugDelivery
    3, 8–11.

    Intranasal drug delivery represents a non-invasive route with the potential (particularly for large
    molecule drugs) to improve convenience, patient comfort, compliance and hence the overall
    efficacy of pharmacological interventions. Here, Henry R Costantino, PhD, Director,
    Formulations; Paul H Johnson, PhD, Senior Vice President, Research & Development and Chief
    Scientific Officer; and Anthony P Sileno, MS, Senior Director, Clinical Affairs & Toxicology (all
    of Nastech Pharmaceutical Company) present a series of case studies illustrating these attributes.
    The technologies they describe demonstrate the versatility of IN drug administration, ranging
    from straightforward formulations of small molecules, to advanced formulations that leverage the
    ability to modulate epithelial tight junctions and enable delivery of peptides and proteins.